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Background
Tuberculosis (TB) complicating HIV-1 infection is a
persistent significant clinical concern, particularly in
resource limited settings. Treatment of HIV-infected
patients with TB often comprises efavirenz-containing
antiretroviral regimens particularly when on TB treat-
ment containing rifampicin. Although rifampicin may
reduce EFV concentrations, little is known of the effect
of the HIV virus or efavirenz on the pharmacokinetics
of rifampicin, particularly in resource limited settings
where the burden of disease exists. We aimed to develop
a low-cost, simple analytical method for the accurate
determination of efavirenz and rifampicin plasma
concentrations.
Methods
Using high-performance liquid chromatography
(HPLC) employing UV detection (1050 series quatern-
ary pump, 1100 series autosampler, a diode array
detector (DAD) and a 1200 series degasser), we devel-
oped and validated a single tube column-based assay
for the detection of rifampicin and efavirenz. Data was
acquired and analysed using Agilent Chemstation for
LC 3D software.
Results
Recovery for plasma samples spiked with the drugs were
>90% for rifampicin and its metabolite deacetylrifampi-
cin and >70% for efavirenz. Intra- and inter-assay preci-
sion relative standard deviation (RSD) values were <4%
in all cases. The assay was validated on 300µl sample
with a runtime of 10 minutes and both drugs measur-
able to concentrations of 100ng/mL.
Discussion
This relatively easy, UV-based assay can accurately
detect efavirenz and rifampicin concentrations within a
clinically relevant concentration range using standard
chromatography equipment, making it potentially
applicable to resource limited settings.
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